Waite Vision在犹他州介绍了使用可调光透镜技术进行视力矫正的未来-动脉网
登录

Waite Vision在犹他州介绍了使用可调光透镜技术进行视力矫正的未来

Waite Vision Introduces the Future of Vision Correction with Light Adjustable Lens Technology in Utah

GlobeNewswire | 2024-04-18 | 翻译由动脉网AI生成,点击反馈

可切换为仅中文


Lehi, April 17, 2024 (GLOBE NEWSWIRE) -- Lehi, Utah - In a significant advancement in the field of ophthalmology, Waite Vision is proud to announce the availability of the Light Adjustable Lens (LAL) procedure, a pioneering vision correction method that promises to redefine standards of care and precision in eye surgery.

Lehi,2024年4月17日(环球通讯社)--犹他州Lehi,作为眼科领域的一项重大进步,Waite Vision骄傲地宣布推出了可调光镜片(LAL)程序,这是一种开创性的视力矫正方法,有望重新定义眼科手术的护理标准和精确度。

This groundbreaking technology, now available in Utah, marks a monumental shift in the way vision correction procedures are performed and perceived, offering a new realm of customization and clarity for patients over 40, and especially those seeking alternatives to traditional eyewear or surgery post cataract removal.

这项开创性的技术现已在犹他州上市,标志着视力矫正程序的执行和感知方式发生了重大转变,为40岁以上的患者,尤其是那些寻求替代传统眼镜或白内障摘除术后手术的患者,提供了定制和清晰的新领域。

For more detail on LAL, Waite Vision has written an article on the subject titled “Light Adjustable Lens Utah”, which can be found on their website here: https://www.waitevision.com/custom-lens-replacement-clr/light-adjustable-lens-utah/ The Light Adjustable Lens, developed by RxSight, represents the culmination of years of research and clinical trials, achieving FDA approval in 2017.

有关LAL的更多详细信息,Waite Vision撰写了一篇题为“光线可调镜头犹他州”的文章,可在其网站上找到:https://www.waitevision.com/custom-lens-replacement-clr/light-adjustable-lens-utah/由RxSight开发的可调光镜片代表了多年研究和临床试验的高潮,于2017年获得FDA批准。

It is the first and only lens of its kind that allows for the adjustment of lens power after the surgical procedure, providing an unparalleled level of precision in vision correction. The LAL procedure begins with the replacement of the eye's natural lens with the Light Adjustable Lens during a refractive cataract surgery or Custom Lens Replacement (CLR).

这是同类产品中第一个也是唯一一个允许在手术后调整镜片功率的镜片,在视力矫正方面提供了无与伦比的精度。LAL手术始于在屈光性白内障手术或定制晶状体置换(CLR)期间用可调光晶状体替代眼睛的自然晶状体。

This is followed by a series of non-invasive adjustments using a specific frequency of ultraviolet light, enabling the fine-tuning of vision to match the patient's needs perfectly. Aaron Waite, MD, of Waite Vision, an expert in the field of refractive surgery, has been at the forefront of adopting this innovative technology, ensuring patients receive the most advanced and effective treatment available tod.

随后,使用特定频率的紫外线进行一系列非侵入性调整,使视力微调能够完美匹配患者的需求。Aaron Waite是屈光手术领域的专家,Waite Vision的医学博士,一直处于采用这项创新技术的前沿,确保患者接受最先进和有效的tod治疗。

推荐阅读

RxSight宣布其最新的可调光透镜™LAL+™商业发布,并在即将到来的ASCRS年会上进行了多次医生演示

GlobeNewswire 2024-04-05 04:05

在“金眼”赛道,诺奖得主也和爱尔康、博士伦抢市场了

李成平 2023-01-07 08:00

我院麻醉学科论文影响力位列全球第一

四川大学华西医院 2024-04-30 11:56

GlobeNewswire

7793篇

最近内容 查看更多

TFF Pharmaceuticals宣布480万美元公开募股定价

4 小时后

Relativity Acquisition宣布收到纳斯达克退市决定

3 小时后

肽疗法开发商Rhythm Pharmaceuticals在《柳叶刀糖尿病与内分泌学》公布Setmelanotide治疗下丘脑肥胖症的2期研究结果

3 小时后

相关公司查看更多

RxSight

眼科医疗器械研发商

立即沟通

产业链接查看更多

所属赛道

其它耗材
近30天,融资9起